 Proactive Investors UK |
GSK says diabetes treatment progressing in trials
Proactive Investors UK Pharmaceutical giant GlaxoSmithKline (LON:GSK) reported its diabetes treatment, albiglutide, has shown “topline results” in seven of its eight final stage studies. Albiglutide is an injectable form of the human peptide GLP-1 which helps maintain normal … GSK: Movement toward FDA filing with weekly diabetes treatmentHULIQ GlaxoSmithKline Drug Studies See Progression for Type-2 Diabetes TreatmentIBTimes.co.uk Glaxo To Seek OK For Diabetes Drug After Trial ResultsWall Street Journal China Post –MedCity News –MarketWatch all 37 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.